Vinge has represented the international private equity firm Cinven and Danish life science investment company Novo Holdings in their sale of Envirotainer Holding AB to EQT X Fund and Mubadala Investment Company, at an enterprise value of about EUR 2.8 billion. Vinge was supported by Clifford Chance.

Envirotainer develops, manufactures and leases active temperature-controlled containers, used primarily for air freighting biopharma products. The company was founded in 1985 in Stockholm and today its R&D, production and headquarters are based in the Stockholm region. With a global presence with about 375 employees in 20 countries and a fleet of about 6,500 containers, Envirotainer is the market leader in air transportation of temperature sensitive pharmaceuticals.

The Vinge team primarily consisted of Christina Kokko, Samra Baytar, Vilhelm Rondahl, Gustav Persson and Ida Redander (M&A), Victoria Gunnerek, Trine Osen Bergqvist and Ebba Thoms (EU, Competition & Regulatory), Linn Adelwald (Banking & finance), Isabell Nielsen and Sam Fakhraie Ardekani (Corporate Commercial), Sara Strandberg, Veronika Garemark, Emil Lindvall and Tove Tullberg (Employment & Corporate Crime), Kristoffer Larson (Real Estate), Axel Lennartsson and Rebecca Målquist (IP), Nicklas Thorgerzon (GDPR), Martin Boström (IT), Johan Cederblad and Lina Österberg (Permits & Environment), Viktoria Owetz Leyva, Christoffer Widström and Sara Dahlros Sköld (VDR).

Related

Vinge advises Sobro on its investment in Västkustens Konstruktionsbyrå

Västkustens Konstruktionsbyrå has decided to broaden its ownership structure by bringing in Sobro as a new co-partner and majority shareholder. The founders will remain with the company as the CEO and CTO respectively, and as significant shareholders. Västkustens Konstruktionsbyrå is an engineering consultancy company based in Gothenburg with cutting-edge expertise in project management, civil engineering and design.
April 23, 2026

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of SEK 350 million before transaction costs.
April 22, 2026

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.
April 20, 2026